MaxCyte (LON:MXCT) Hits New 12-Month Low at $275.00

MaxCyte, Inc. (LON:MXCT)’s stock price hit a new 52-week low on Friday . The company traded as low as GBX 275 ($3.44) and last traded at GBX 275 ($3.44), with a volume of 61486 shares traded. The stock had previously closed at GBX 285 ($3.57).

MaxCyte Price Performance

The company has a quick ratio of 14.38, a current ratio of 17.92 and a debt-to-equity ratio of 6.72. The business has a 50-day moving average price of GBX 325.58 and a two-hundred day moving average price of GBX 350.37. The company has a market capitalization of £292.39 million, a price-to-earnings ratio of -1,130.00 and a beta of 0.78.

Insider Transactions at MaxCyte

In other news, insider John Johnston sold 118 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of GBX 480 ($6.01), for a total transaction of £566.40 ($708.80). 1.19% of the stock is owned by insiders.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.